Moderna shares fell as much as 25% following the release of results for its cancer vaccine. The vaccine reduced the risk of melanoma recurrence or death by 42%. The decline reflected extremely high market expectations, which weighed on the stock despite the favorable clinical data.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
